Brain imaging AI start-up Neurophet raises $15M to better direct Alzheimer ’s treatments, lower ARIA side-effects
Korean AI startups Allganize, Neurophet raise over $35 mn (The Korea Economic Daily):
Founded in 2016, the company plans to next year roll out its new AI analysis program that can detect side effects of Alzheimer’s disease treatments with a microhemorrhage diagnosis.
The Korean AI startup is famous for its flagship AI analysis technologies, Neurophet AQUA, which is a brain MRI analysis technology, and Neurophet SCALE PET, an AI-based positron emission tomography (PET) image analysis program.
It plans to go public in Korea next year, said Neurophet CEO Bin Joon-gil, adding that it is currently working with its underwriter Mirae Asset Securities for the IPO.
The Announcement:
Neurophet secures 20 billion in Series C funding to launch AI dementia treatment solution (Korea Biomedical Review):
Alzheimer’s drugs such as lecanemab and donanemab, being developed and launched by global pharmaceutical companies, are anti-amyloid antibody treatments that aim to remove amyloid beta … Amyloid-PET imaging is required before prescribing treatment to determine whether amyloid beta is deposited in the cerebral cortex and whether it decreases afterward.
Neurophet has developed Neurophet SCALE PET, a software that automatically analyzes amyloid-PET images that would otherwise require a time-consuming manual analysis by radiologists.
Neurophet SCALE PET combines PET and MRI images to analyze Alzheimer’s disease biomarkers such as amyloid beta protein and tau protein at ultra-high sp...
Source: SharpBrains - Category: Neuroscience Authors: SharpBrains Tags: Brain/ Mental Health Technology & Innovation Alzheimer’s disease treatments Alzheimers-disease anti-amyloid antibody treatments brain image analysis donanemab lecanemab microhemorrhage diagnosis Neurophet positron emission tomography Source Type: blogs
More News: Alzheimer's | Brain | Dementia | Funding | Men | Neurology | Neuroscience | PET Scan | Radiology | Women